- Amylyx Pharmaceuticals received FDA Fast Track designation on August 7, 2025, for treatments aimed at ALS, including evaluating avexitide post-RYGB surgery.
- Avexitide received FDA Breakthrough Therapy designation.
Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
3 reports, 1 independent
Updated Aug 18
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Amylyx Pharmaceuticals
American biopharmaceutical company
Nothing else this week.
Related events
- The FDA recommended advancement for a new drug application submitted by a company.
- The FDA is reviewing a drug approval application for a condition involving the company GAD.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.